Actively Recruiting
Phase 1b Study of HC-7366 with Belzutifan WELIREG for Advanced or Metastatic Renal Cell Carcinoma
Led by HiberCell, Inc. · Updated on 2026-10-02
80
Participants Needed
21
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1b, open-label study to evaluate the safety, tolerability, and efficacy of HC-7366 in combination with belzutifan WELIREG in patients with locally advanced inoperable or metastatic renal cell carcinoma RCC with predominantly clear cell histology. The study aims to determine the maximum tolerated dose of HC-7366 when used with belzutifan, regardless of VHL gene mutation status. The study includes multiple parts a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will participate, with up to 20 receiving HC-7366 alone at a dose to be determined, and up to 60 receiving a combination of HC-7366 and belzutifan 120 mg daily. The treatments are given orally each day. Participants will be monitored over about 30 months to assess the highest safe dose and recommended phase 2 dose for the combination. Researchers will track safety and treatment effects during this time. The study is open-label and non-randomized, with regular assessments to evaluate tolerability and efficacy throughout the treatment period.
CONDITIONS
Brief Title
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Research Team
M
Michele Gargano
P
Paulette Mattson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here